Literature DB >> 20308477

MRI in lipid-lowering agent-associated myopathy: a retrospective review of 21 cases.

Soeren A Peters1, Rudolf Kley, Martin Tegenthoff, Matthias Vorgerd, Volkmar Nicolas, Christoph M Heyer.   

Abstract

OBJECTIVE: The objective of our study was to identify disease-specific patterns of myopathic changes in patients with lipid-lowering agent (LLA)-associated myopathy using a dedicated MRI protocol.
MATERIALS AND METHODS: Axial T1- and T2-weighted STIR images were obtained for the detection of lipomatosis and edema, respectively, of the thighs and legs. Information about patient age, sex, duration of dyslipidemia and of medication use, latency of symptom onset, maximum creatine kinase (CK) level, presence of myalgia and muscle weakness, and LLA or LLAs used was collected.
RESULTS: Significant correlations resulted for the radiologic diagnosis of LLA-associated myopathy and maximum CK level; the presence of edema and maximum CK level; edema and weakness in the ventral thigh muscle group, thigh adductors, or deep dorsal muscle group of the legs; and lipomatosis and weakness of the deep dorsal muscle group of the legs and peroneal muscle group, respectively.
CONCLUSION: MRI is a method that helps detect active pathologic processes in patients with suspected LLA-associated myopathy but does not reveal disease-specific patterns.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308477     DOI: 10.2214/AJR.09.2698

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  2 in total

1.  Colchicine Myopathy: A Case Series Including Muscle MRI and ABCB1 Polymorphism Data.

Authors:  Mehul Gupta; Ana Nikolic; Denise Ng; Kristina Martens; Hamid Ebadi; Sameer Chhibber; Gerald Pfeffer
Journal:  Front Neurol       Date:  2019-05-24       Impact factor: 4.003

Review 2.  Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus.

Authors:  Emilio Filippucci; Walter Grassi; Andrea Di Matteo; Gianluca Smerilli; Edoardo Cipolletta; Fausto Salaffi; Rossella De Angelis; Marco Di Carlo
Journal:  Curr Rheumatol Rep       Date:  2021-07-16       Impact factor: 4.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.